1. Abe J, Nakano T, Nishii Y, Matsumoto T, Ogata E, Ikeda K (1991) A novel vitamin D3 analog, 22-oxa-1,25-dihydroxyvitamin D3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832–837
2. Abe-Hashimoto J, Kikuchi T, Matsumoto T, Nishii Y, Ogata E, Ikeda K (1993) Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 53:2534–2537
3. Binderup L, Latini S, Binderup E, Bretting C, Calverley M, Hansen K (1991) 20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 42:1569–1575
4. Bouillon R, Okamura WH and Norman AW (1995) Structure-function relationships in the vitamin D endocrine system. Endocrine Rev 16:200–257 Buras RR, Schumaker LM, Davoodi F, Brenner RV, Shabahang M, Nauta RJ, Evans SR (1994) Vitamin D receptors in breast cancer cells. Breast Cancer Res Treat 31:191–202
5. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP (1997a) Inhibition of prostate cancer cells by 19-nor-hexafluride vitamin D3 analogues correlates with their induction of p21waf1, p27kip1 and E-cadherin. J Mol Endocrinol 19:15–27